Walmart Earnings: Holiday Shopping Is Off to a Strong Start
The retailer said sales rose during the most recent quarter, propelled by shoppers buying groceries, home goods and toys-a sign that spending is off to a steady start this holiday season.
Lowe's Stock Falls After Earnings. It's 'Too Early to Call an Inflection Point.'
The home-improvement retailer reported a strong third quarter, and raised its financial forecasts.
Alex Jones Sues Sandy Hook Families Over Infowars Sale
Attorneys for Jones said the satirical website made an illegitimate bid for Infowars and plans to misuse its intellectual property.
MicroStrategy Market Value Tops $100 Billion as Bitcoin Hits New High
Shares of the bitcoin holder are up 11.2% Tuesday to $427.96, continuing its rally with the stock nearly doubling since the Nov. 5 election.
Volkswagen Chooses Rivian's Kjell Gruner to Lead U.S. Business
The German car maker said Gruner would take over as chief executive of Volkswagen's America operations on Dec. 12.
Google's $2 Billion Anthropic Investment Gets U.K. Antitrust Clearance
The Competition and Markets Authority said it wouldn't open an in-depth investigation into Google's investment in the AI startup.
Employers Get Pressure to Pay for Drugs Like Wegovy
Eli Lilly and Novo Nordisk representatives get face time with companies in hopes they will cover their weight-loss drugs.
Merck says blockbuster cancer drug met goals in trial of new formulation
The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.
Biden Team Races to Deliver Chip Grants Before Trump Takes Over
Government officials and chip makers like Intel are in talks over billions of dollars aimed at growing domestic manufacturing.
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest starter dose.
(END) Dow Jones Newswires
November 19, 2024 17:00 ET (22:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments